Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms (ACA4)

Assistance Publique - Hôpitaux de Paris

Status and phase: Unknown; Phase 2

Conditions: Small Abdominal Aortic Aneurysm; Abdominal Aortic Aneurysm,

Treatments: Drug: Cyclosporine A; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02225756

P110119

Details and patient eligibility

About

Aneurysms of the aorta are dilatations of the main artery in the body that distributes blood to organs. Aneurysms expose patients to aortic rupture. The risk of aortic rupture is high for large aneurysms, and low for small aneurysms. Currently, if the diameter of a small aneurysm grows up to a level at risk for rupture, surgery is indicated to prevent rupture. A drug that would stop growth of small aneurysms would obviate aortic surgery, the current treatment to prevent aortic rupture in patients. The ACA4 study aims at testing the possibility to stop growth of small aortic aneurysms in the abdomen with a drug, cyclosporine A. Patients with small aneurysms will receive cyclosporine A orally, or a placebo (fake liquid), every day during a short period of time. Efficacy of the drug will be evaluated by measuring the diameter of the aneurysm during 2 years after treatment cessation. Drug safety analysis will evaluate the impact of the drug on renal function, blood pressure, and other parameters. In case of adverse event during the drug administration phase, dose of the drug or of the placebo will be decreased or administration stopped.

Full description

Abdominal aortic aneurysms (AAAs) expose patients to death caused by aortic rupture. Although screening of AAAs has been shown to decrease AAA-related mortality, translation into medical practice of screening is limited because there is no specific treatment to limit growth of AAAs below diameter thresholds for open surgery or stent graft. We have developed different approaches aimed at inducing healing and thereby stabilizing formed AAAs in animal models. We have identified TGF-beat1 as an inducer of experimental AAA healing. Cyclosporine A is an inducer of tumor growth factor - beta1 (TGF-beta1) in experimental AAAs and in human atherosclerotic AAAs in vitro, causing overgrowth of inflamed tissues. Since AAAs are caused by aortic wall atrophy, we have hypothesised and confirmed in animals, that cyclosporine AAA, when administrated during a short period of time, durably stabilizes small AAA diameter in animals, while inducing aortic wall reconstruction and healing.

The clinical trial ACA4 is a multicentric randomized, placebo controlled, double blind trial that will enrol 360 patients with small AAAs in France. Two doses of cyclosporine A will be tested against a placebo (three arms). Drug administration will be short, and AAA diameter evaluation will be performed for 2 years, by CT-scanner (main outcome) with no contrast, and duplex-scanner.

Enrollment: 360 estimated patients

Sex: All

Ages: 50 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male patients with asymptomatic AAA ≥ 30 mm, ≤ 49 mm
• Female patients with asymptomatic AAA ≥ 25 mm, ≤ 44 mm

Exclusion criteria

• Common iliac aneurysm > 25 mm
• Saccular aneurysm of the aorta
• Inflammatory aneurysm
• No signature of informed consent
• Renal dysfunction
• Diabetes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

360 participants in 3 patient groups, including a placebo group

Cyclosporine A dose 1

Experimental group

Treatment:

Drug: Cyclosporine A

Drug: Cyclosporine A

Cyclosporine A dose 2

Experimental group

Treatment:

Drug: Cyclosporine A

Drug: Cyclosporine A

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo